OA11664A - Controlled-release pharmaceutical formulations containing a cGMP PDE-5 inhibitor. - Google Patents

Controlled-release pharmaceutical formulations containing a cGMP PDE-5 inhibitor. Download PDF

Info

Publication number
OA11664A
OA11664A OA1200100093A OA1200100093A OA11664A OA 11664 A OA11664 A OA 11664A OA 1200100093 A OA1200100093 A OA 1200100093A OA 1200100093 A OA1200100093 A OA 1200100093A OA 11664 A OA11664 A OA 11664A
Authority
OA
OAPI
Prior art keywords
formulation
inhibitor
release
cgmp pde
daims
Prior art date
Application number
OA1200100093A
Other languages
English (en)
Inventor
Elizabeth King
Ross James Macrae
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11664(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9823192.1A external-priority patent/GB9823192D0/en
Priority claimed from GBGB9825117.6A external-priority patent/GB9825117D0/en
Priority claimed from GBGB9826392.4A external-priority patent/GB9826392D0/en
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of OA11664A publication Critical patent/OA11664A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
OA1200100093A 1998-10-23 1999-10-04 Controlled-release pharmaceutical formulations containing a cGMP PDE-5 inhibitor. OA11664A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9823192.1A GB9823192D0 (en) 1998-10-23 1998-10-23 Pharmaceutical formulations
GBGB9825117.6A GB9825117D0 (en) 1998-11-16 1998-11-16 Pharmaceutical formulations
GBGB9826392.4A GB9826392D0 (en) 1998-11-27 1998-11-27 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
OA11664A true OA11664A (en) 2005-01-07

Family

ID=27269526

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100093A OA11664A (en) 1998-10-23 1999-10-04 Controlled-release pharmaceutical formulations containing a cGMP PDE-5 inhibitor.

Country Status (44)

Country Link
US (1) US6964780B1 (is)
EP (1) EP1123088B1 (is)
JP (1) JP2002528408A (is)
KR (1) KR20010075659A (is)
CN (1) CN1324233A (is)
AP (1) AP2001002125A0 (is)
AT (1) ATE340562T1 (is)
AU (1) AU756509B2 (is)
BG (1) BG65323B1 (is)
BR (1) BR9914718A (is)
CA (1) CA2348086C (is)
CO (1) CO5160262A1 (is)
CR (1) CR6326A (is)
CY (1) CY1106239T1 (is)
CZ (1) CZ20011427A3 (is)
DE (1) DE69933383T2 (is)
DK (1) DK1123088T3 (is)
DZ (1) DZ2923A1 (is)
EA (1) EA004068B1 (is)
EE (1) EE200100235A (is)
ES (1) ES2272082T3 (is)
GT (1) GT199900184A (is)
HK (1) HK1041818A1 (is)
HR (1) HRP20010285A2 (is)
HU (1) HUP0104318A3 (is)
ID (1) ID28232A (is)
IL (1) IL141764A (is)
IS (1) IS5865A (is)
MA (1) MA26700A1 (is)
MX (1) MXPA01004011A (is)
MY (1) MY130727A (is)
NO (1) NO20011933L (is)
NZ (1) NZ510275A (is)
OA (1) OA11664A (is)
PA (1) PA8484301A1 (is)
PE (1) PE20001286A1 (is)
PL (1) PL195789B1 (is)
PT (1) PT1123088E (is)
SK (1) SK286473B6 (is)
TR (1) TR200101103T2 (is)
TW (1) TW577756B (is)
UA (1) UA67802C2 (is)
UY (1) UY25765A1 (is)
WO (1) WO2000024383A1 (is)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295436A1 (de) * 1997-11-12 2011-03-16 Bayer Schering Pharma AG 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren
DE69939748D1 (de) 1998-11-02 2008-11-27 Elan Pharma Int Ltd Multipartikuläre zusammensetzung von methylphenidat mit modifizierter freisetzung
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU8444401A (en) * 2000-09-06 2002-03-22 Tanabe Seiyaku Co Preparations for oral administration
WO2002036099A1 (en) 2000-10-30 2002-05-10 Euro-Celtique S.A. Controlled release hydrocodone formulations
KR100750554B1 (ko) * 2001-02-15 2007-08-20 다나베 세이야꾸 가부시키가이샤 구강 내 속붕괴성 정제
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
ITMI20020515A1 (it) * 2002-03-12 2003-09-12 Jagotec Ag Sistema per il rilasco controllato di uno o piu' principi attivi
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
AU2005239962B2 (en) 2004-05-11 2011-07-07 Eb Ip Lybrido B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
DE102004023069A1 (de) 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
GB0421121D0 (en) * 2004-09-22 2004-10-27 Natrocell Technologies Ltd Composite rodenticide
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
CA2613617A1 (en) * 2005-06-27 2007-01-04 Daniel Drai Compositions and methods for enhancement of sexual function
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
EP1931797A2 (en) * 2005-09-29 2008-06-18 Bayer HealthCare AG Pde inhibitors and combinations thereof for the treatment of urological disorders
EP1945214A1 (en) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP2037927B1 (en) 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin for the treatment of urinary incontinence and related diseases
BRPI0716439B8 (pt) 2006-08-14 2021-05-25 Boehringer Ingelheim Int sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos
CN101505736A (zh) 2006-08-25 2009-08-12 贝林格尔.英格海姆国际有限公司 控制释放系统及其制造方法
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
US20080226715A1 (en) * 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods
KR20100029762A (ko) * 2007-06-13 2010-03-17 바이엘 쉐링 파마 악티엔게젤샤프트 청력 장애 치료용 ｐｄｅ 억제제
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
US20110033506A1 (en) * 2008-02-08 2011-02-10 Adel Penhasi Combination dosage form of low-dose modafinil and low-dose sildenafil
MX339136B (es) * 2008-12-12 2016-05-13 Rhein Siegfried Sa De Cv Composicion de liberacion pulsatil de sildenafil y proceso para prepararla.
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
EA015250B9 (ru) * 2010-11-19 2013-10-30 Тева Фармасьютикал Индастриз, Лтд. Таблетка силденафила, обеспечивающая модифицированную фармакокинетику, и способ ее изготовления
MX353623B (es) 2011-05-13 2018-01-22 Eb Ip Hybritabs B V Sistema de suministro de farmaco.
WO2013016144A1 (en) * 2011-07-22 2013-01-31 Pom Wonderful, Llc Compositions comprising pomegranate polyphenols in combination with erectile dysfunction-treating compounds, and methods of treating erectile dysfunction therewith
WO2017168174A1 (en) * 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN113995727B (zh) * 2021-11-08 2023-04-07 山东鲁抗医药股份有限公司 一种5型磷酸二酯酶抑制剂片剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
JPS54119021A (en) * 1978-03-06 1979-09-14 Nippon Kayaku Co Ltd Carcinostatic agent
CH648754A5 (en) * 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
JPS5748908A (en) * 1980-09-08 1982-03-20 Kyorin Pharmaceut Co Ltd Prolonged release type nicomol pharmaceutical
FR2624732B1 (fr) 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
MC2025A1 (fr) * 1988-04-20 1990-04-25 Asta Pharma Ag Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
IT1229856B (it) * 1989-04-20 1991-09-13 Recordati Chem Pharm Compresse a rilascio controllato contenenti flavossato.
US5474784A (en) 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
ES2149250T3 (es) * 1993-04-23 2000-11-01 Novartis Ag Dispositivo para la administracion de medicamentos con liberacion controlada.
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
AU2976897A (en) * 1996-06-18 1998-01-07 Otsuka Pharmaceutical Co., Ltd. Multiple-unit type prolonged action drug preparation
JPH1067657A (ja) * 1996-06-18 1998-03-10 Otsuka Pharmaceut Co Ltd マルチプルユニット型持続性製剤
CN1244119A (zh) * 1997-01-06 2000-02-09 辉瑞大药厂 迅速释放和掩蔽味觉的药物剂型
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6277884B1 (en) * 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
DE69916627T2 (de) * 1998-09-04 2005-07-28 Ortho-Mcneil Pharmaceutical, Inc. 5-heterozyklyl-pyrazolo[4,3-d]pyrimidin-7-one für die behandlung von männlichen erectilen dysfunktionen

Also Published As

Publication number Publication date
AU5878799A (en) 2000-05-15
GT199900184A (es) 2001-04-14
CY1106239T1 (el) 2011-06-08
MXPA01004011A (es) 2003-03-10
JP2002528408A (ja) 2002-09-03
MA26700A1 (fr) 2004-12-20
DZ2923A1 (fr) 2004-03-01
DE69933383D1 (de) 2006-11-09
BG65323B1 (bg) 2008-02-29
DE69933383T2 (de) 2007-02-01
CZ20011427A3 (cs) 2001-10-17
MY130727A (en) 2007-07-31
HK1041818A1 (zh) 2002-07-26
PE20001286A1 (es) 2000-11-22
PA8484301A1 (es) 2000-09-29
NO20011933D0 (no) 2001-04-19
PL195789B1 (pl) 2007-10-31
EP1123088A1 (en) 2001-08-16
DK1123088T3 (da) 2007-01-02
NZ510275A (en) 2003-07-25
CA2348086A1 (en) 2000-05-04
SK5192001A3 (en) 2002-09-10
IS5865A (is) 2001-02-27
UA67802C2 (uk) 2004-07-15
US6964780B1 (en) 2005-11-15
ES2272082T3 (es) 2007-04-16
WO2000024383A1 (en) 2000-05-04
ATE340562T1 (de) 2006-10-15
PL347476A1 (en) 2002-04-08
ID28232A (id) 2001-05-10
EP1123088B1 (en) 2006-09-27
HUP0104318A3 (en) 2003-12-29
HUP0104318A2 (hu) 2002-03-28
HRP20010285A2 (en) 2002-06-30
UY25765A1 (es) 2001-08-27
EA004068B1 (ru) 2003-12-25
BR9914718A (pt) 2001-07-10
BG105465A (bg) 2001-12-29
PT1123088E (pt) 2007-01-31
IL141764A0 (en) 2002-03-10
KR20010075659A (ko) 2001-08-09
CA2348086C (en) 2007-01-23
AP2001002125A0 (en) 2001-04-04
EE200100235A (et) 2002-08-15
TW577756B (en) 2004-03-01
CR6326A (es) 2004-02-23
TR200101103T2 (tr) 2001-09-21
AU756509B2 (en) 2003-01-16
NO20011933L (no) 2001-06-25
CN1324233A (zh) 2001-11-28
CO5160262A1 (es) 2002-05-30
EA200100298A1 (ru) 2001-08-27
IL141764A (en) 2008-06-05
SK286473B6 (sk) 2008-11-06

Similar Documents

Publication Publication Date Title
AU756509B2 (en) Controlled-release pharmaceutical formulations containing a cGMP PDE-5 inhibitor
KR101465077B1 (ko) 다폭세틴을 포함하는 시간차 서방출 경구투여형 약학적 조성물
US20080031948A1 (en) Sustained-release bupropion and bupropion/mecamylamine tablets
PL188919B1 (pl) Doustna, multijednostkowa kompozycja preparatu farmaceutycznego o modyfikowanym uwalnianiu oraz sposób wytwarzania jednostki dawkowania doustnej multijednostkowej kompozycji farmaceutycznej o modyfikowanym uwalnianiu
AU2009220444A1 (en) Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-IV inhibitor
WO2007020337A1 (fr) Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte et son application therapeutique
EP1745775A1 (en) Gastroretentive formulations and manufacturing process thereof.
EP1077065B1 (en) Controlled release formulations
KR102239291B1 (ko) 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
PL200858B1 (pl) Jednostka dawkowania do podawania doustnie zawierająca mirtazapinę
EP2010158B1 (en) Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
ZA200102957B (en) Controlled-release pharmaceutical formulations containing a cGMP PDE-5 inhibitor.
US20080206338A1 (en) Controlled release formulations of an alpha-adrenergic receptor antagonist
MX2011013159A (es) Tableta orodispersable de sildenafil y metodo para preparar la misma.
TW202313072A (zh) 檸檬酸鐵之兒科調配物
NZ760868B2 (en) A solid oral fixed dose composition comprising metformin, valsartan and atorvastatin
KR20050085386A (ko) 불안증 치료 방법 및 조성물